763 related articles for article (PubMed ID: 28365930)
1. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
Argyrou C; Moris D; Vernadakis S
J BUON; 2017; 22(1):6-20. PubMed ID: 28365930
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
5. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets.
Chen Y; Wang W; Morgan MP; Robson T; Annett S
Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533
[TBL] [Abstract][Full Text] [Related]
6. [The Development of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease].
Kwon OS; Kim JH; Kim JH
Korean J Gastroenterol; 2017 Jun; 69(6):348-352. PubMed ID: 28637103
[TBL] [Abstract][Full Text] [Related]
7. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
8. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease.
Degasperi E; Colombo M
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):156-164. PubMed ID: 28404072
[TBL] [Abstract][Full Text] [Related]
9. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].
Pár A; Pár G
Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838
[TBL] [Abstract][Full Text] [Related]
10. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
Marengo A; Rosso C; Bugianesi E
Annu Rev Med; 2016; 67():103-17. PubMed ID: 26473416
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
12. A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.
Michel M; Kalliga E; Labenz C; Straub BK; Wörns MA; Galle PR; Schattenberg JM
Z Gastroenterol; 2020 Jan; 58(1):57-62. PubMed ID: 31931541
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma and non-alcoholic fatty liver disease.
Golabi P; Rhea L; Henry L; Younossi ZM
Hepatol Int; 2019 Nov; 13(6):688-694. PubMed ID: 31701393
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.
Reeves HL; Zaki MY; Day CP
Dig Dis Sci; 2016 May; 61(5):1234-45. PubMed ID: 26921078
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil.
Torres DM; Harrison SA
Semin Liver Dis; 2012 Feb; 32(1):30-8. PubMed ID: 22418886
[TBL] [Abstract][Full Text] [Related]
16. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
Margini C; Dufour JF
Liver Int; 2016 Mar; 36(3):317-24. PubMed ID: 26601627
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Massoud O; Charlton M
Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
[TBL] [Abstract][Full Text] [Related]
18. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; French B; Tillman B; French S
Exp Mol Pathol; 2018 Aug; 105(1):144-149. PubMed ID: 30009772
[TBL] [Abstract][Full Text] [Related]
19. Management and diagnosis of fatty liver disease.
Schneier AT; Citti CC; Dieterich DT
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):671-83. PubMed ID: 25716275
[TBL] [Abstract][Full Text] [Related]
20. Minimally invasive percutaneous endovascular therapies in the management of complications of non-alcoholic fatty liver disease (NAFLD): A case report.
Salsamendi J; Pereira K; Kang K; Fan J
J Radiol Case Rep; 2015 Sep; 9(9):36-43. PubMed ID: 26629307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
